December 2, 2015
Flood in Chennai suspends operations at Natco Pharma API plant (India)
Flood in India’s Chennai suspends operations at Natco Pharma API plant
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
December 1, 2015
Savy Akers’ production facility in China fully operational
Savy Akers’ 10,000 square foot production facility in Haikou National Hi-Tech Industrial Zone, Hainan province, is now fully operational.
December 1, 2015
Celyad advances first NKG2D CAR T-Cell Phase I study
Celyad advances first NKG2D CAR T-Cell Phase I study
December 1, 2015
French Biophytis appoints new Director of Research
Biophytis has appointed Pierre J. Dilda, PhD, as Director of
Research.
December 1, 2015
Frances Neovacs engaging in immuno-oncology
Neovacs, a France-based specialist in active immunotherapies for the treatment of autoimmune diseases, has decided to engage in the field of immuno-oncology after a recommendations by its Scientific Adivsory Board
December 1, 2015
Tuberculosis funding gap threatens elimination goals
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
December 1, 2015
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target
November 30, 2015
European Commission approves Horizon’s Ravicti for treating Urea Cycle Disorders
Horizon Pharma and its affiliate, Horizon Therapeutics, has gotten the European Commission’s (EC’s) approval for Ravicti – glycerol phenylbutyrate – Oral Liquid for use as an adjunctive therapy for chronic management patients with six subtypes of Urea Cycle Disorders (UCDs).
November 30, 2015
PureTech Health launches Scientific Advisory Board
Boston-based PureTech Health plc has launched a Scientific Advisory Board (SAB) of distinguished scientists and physicians, and the expansion of PureTech’s senior team.
November 30, 2015
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy